scholarly journals Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia

2016 ◽  
Vol 11 (2) ◽  
pp. 80-85 ◽  
Author(s):  
Kathryn E. Flynn ◽  
Ehab Atallah
Keyword(s):  
Quality Of Life ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Term Therapy ◽  
Long Term Therapy

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Blood ◽  
2011 ◽  
Vol 118 (17) ◽  
pp. 4554-4560 ◽  
Author(s):  
Fabio Efficace ◽  
Michele Baccarani ◽  
Massimo Breccia ◽  
Giuliana Alimena ◽  
Gianantonio Rosti ◽  
...  
Keyword(s):  
Quality Of Life ◽  
General Population ◽  
Myeloid Leukemia ◽  
Term Therapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Long Term Therapy

Abstract The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.

Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy

2017 ◽  
Vol 21 (3) ◽  
pp. 565-569 ◽  
Author(s):  
Tanja Kraus ◽  
Kathrin Gegenleitner ◽  
Martin Svehlik ◽  
Michael Novak ◽  
Gerhardt Steinwender ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cerebral Palsy ◽  
Intrathecal Baclofen ◽  
Spastic Cerebral Palsy ◽  
Term Therapy ◽  
Long Term Therapy

scholarly journals Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis

2020 ◽  
Vol 9 (1) ◽  
pp. 154 ◽  
Author(s):  
Fabio Barra ◽  
Carolina Scala ◽  
Umberto Leone Roberti Maggiore ◽  
Simone Ferrero
Keyword(s):  
Quality Of Life ◽  
Oral Treatment ◽  
Fourth Generation ◽  
Term Therapy ◽  
Deep Endometriosis ◽  
Wide Range ◽  
Intestinal Symptoms ◽  
Long Term Therapy

Background: Rectosigmoid endometriosis is a severe form of deep endometriosis, which may be responsible for pain symptoms and a wide range of intestinal complains such as diarrhea, constipation, and abdominal cramping. The primary objective of this study was to evaluate the efficacy of long-term therapy with dienogest (DNG), a fourth-generation progestin, for ameliorating quality of life, pain, and intestinal symptoms of patients affected by rectosigmoid endometriosis. Methods: A retrospective analysis of a prospectively collected database was done on patients with endometriotic nodules infiltrating at least the muscular layer of the rectosigmoid wall with an estimated colorectal stenosis <60%. The diagnosis of rectosigmoid endometriosis was based on transvaginal ultrasonography. Patients accepting to participate in the study received continuous oral treatment with DNG at the dose of 2 mg/day. Results: At the end of the first year of treatment, a significant decrease in dysmenorrhea (P < 0.001), chronic pelvic pain (P < 0.001), dyspareunia (P < 0.001), dyschezia (P < 0.001), and in intestinal symptoms (P < 0.001) was observed. A progressive increase of the Endometriosis Health Profile-30 (EHP-30) and Gastrointestinal Quality of Life Index (GIQLI) scores was observed in the first two years of therapy (P < 0.001 and P < 0.001, respectively). Improvements of patients’ symptoms and quality of life were maintained until the end of the study. The regimen was well tolerated, and the frequency and amount of irregular bleeding decreased as treatment progressed. Conclusion: The current study confirms the efficacy of long-term therapy with DNG for treating symptoms caused by rectosigmoid endometriosis.

scholarly journals Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Blood ◽  
2011 ◽  
Vol 117 (14) ◽  
pp. 3733-3736 ◽  
Author(s):  
Amr R. Ibrahim ◽  
Lina Eliasson ◽  
Jane F. Apperley ◽  
Dragana Milojkovic ◽  
Marco Bua ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Cytogenetic Response ◽  
Poor Adherence ◽  
Adherence Rate ◽  
Lower Probability ◽  
Term Therapy ◽  
Molecular Response ◽  
Long Term Therapy

Abstract We studied the relation between adherence to imatinib measured with microelectronic monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) and of imatinib failure in 87 CCyR chronic myeloid leukemia patients receiving long-term therapy. We included in our analysis the most relevant prognostic factors described to date. On multivariate analysis, the adherence rate and having failed to achieve a major molecular response were the only independent predictors for loss of CCyR and discontinuation of imatinib therapy. The 23 patients with an adherence rate less than or equal to 85% had a higher probability of losing their CCyR at 2 years (26.8% vs 1.5%, P = .0002) and a lower probability of remaining on imatinib (64.5% vs 90.6%, P = .006) than the 64 patients with an adherence rate more than 85%. In summary, we have shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy.

scholarly journals Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2118-2118
Author(s):  
Lisi Huang ◽  
Xin Du ◽  
Jianyu Weng ◽  
Peilong Lai ◽  
Zesheng Lu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Myeloid Leukemia ◽  
Social Functioning ◽  
General Hospital ◽  
Conflict Of Interest ◽  
Myeloid Leukemia ◽  
Medical Outcome ◽  
Allogeneic Transplant

Abstract Comparison of the 5 year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia treated with Imatinib or Allogeneic Transplant Jianyu Weng1*, Lisi Huang1*, Peilong Lai1, Zesheng Lu1, Ping Wu1, Suijing Wu1, Chengwei Luo1, Wei Ling1, Chenxin Deng1, Xin Huang1, Suxia Geng1, Xin Du1? 1Department of Hematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, P.R. China. *These authors contributed equally to this work.? Corresponding author: Xin Du, MD, Ph.D. 106. Zhongshan Er Rd, Guangzhou, 510080, P.R. China E-mail: [email protected] Phone: (86)-20-83827812-62122 Fax: (86)-20-83889772 Abstract To evaluate and compare the long-term medical outcome and health-related quality of life (HRQOL) of patients with CML in chronic phase (CML-CP) who received imatinib or an allogeneic hematopoietic stem cell transplant (allo-HSCT) using retrospective analysis and an embedded cross-sectional study. CML-CP patients who received imatinib or transplantation from January 4, 2004 to October 10, 2011 in the Department of Hematology at Guangdong General Hospital (GGH) were enrolled in this study. A total of 131 patients, including 90 and 41 in the imatinib and allo-HSCT groups, respectively, were enrolled. The two groups including HRQOL investigation were well matched for gender, marital status, employment status, educational background, and Sokal score at diagnosis. There were no significant differences in the five-year EFS, PFS and OS between the two groups. The HRQOL was measured using EORTC QLQ-C30. Those questions include five multi-item function scales (Physical, Role, Emotional, Cognitive and Social Functioning), a combined Global Health Status/QOL scale, and a number of individual items (appetite loss, dyspnea, diarrhea, constipation, sleep disturbances, and financial impact). In terms of HRQOL, with the exception of social functioning (64.9 vs. 77.5, P=0.035), there was no significant difference in many of the HRQOL scores between the imatinib and transplant groups: global HRQOL, role function, physical function, emotional function and cognitive function. However, symptoms including nausea/vomiting (14.8 vs. 3.2, P=0.013), diarrhea (18.4 vs. 2.5, P=0.001), and financial difficulty (56.9 vs. 33.3, P=0.023) more negatively impacted the imatinib group (P<0.05). Persistent cGVHD reduced the HRQOL of the allo-HSCT group, compared with the non-cGVHD and historic cGVHD group. Although imatinib and transplantation have similar long-term medical outcomes, allo-HSCT provides better social function, moderate symptoms, and lower financial burden. Thus, the role of allo-HSCT for CML-CP should be reevaluated in developing countries in the era of TKIs. Keywords: chronic myeloid leukemia; quality of Life CONFLICT OF INTEREST The authors declare no conflict of interest. ACKNOWLEDGMENTS This work was supported by the National Natural Science Foundation of China (Grant No. 81270648, 81300446 and 81370665), Science and Technology Planning Project of Guangzhou (Grant No.201400000003-4, 201400000003-1). Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document